{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:08:26Z","timestamp":1790021306667,"version":"4.0.1"},"reference-count":197,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>Gene therapy is an approach that employs vectors to deliver genetic material to target cells, aiming to correct genes with pathogenic mutations and modulate one or more genes responsible for disease progression. It holds significant value for clinical applications and offers broad market potential due to the large patient population affected by various conditions. For instance, in 2023, the Food and Drug Administration (FDA) approved 55 new drugs, including five specifically for gene therapy targeting hematologic and rare diseases. Recently, with advancements in understanding the pathogenesis and development of neurodegenerative diseases (NDDs), gene therapy has emerged as a promising avenue for treating Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA), particularly in personalized medicine. Notably, the FDA has approved three clinical applications for combating SMA, utilizing viral vectors delivered via intravenous and intrathecal injections. However, gene therapy for other NDDs remains in clinical trials, necessitating improvements in viral vectors, exploration of new vectors, optimization of delivery routes, and further investigation into pathogenesis to identify novel targets. This review discusses recent advancements in gene therapy for NDDs, offering insights into developing new therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fnins.2025.1515255","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:25:55Z","timestamp":1746681955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Significance of gene therapy in neurodegenerative diseases"],"prefix":"10.3389","volume":"19","author":[{"given":"Lingling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoxue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109928","DOI":"10.1016\/j.msec.2019.109928","article-title":"The recent progresses in shRNA-nanoparticle conjugate as a therapeutic approach","volume":"104","author":"Acharya","year":"2019","journal-title":"Mater Sci. Eng. C Mater Biol. Appl."},{"key":"B2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jconrel.2017.12.029","article-title":"High-efficiency transduction of spinal cord motor neurons by intrauterine delivery of integration-deficient lentiviral vectors","volume":"273","author":"Ahmed","year":"2018","journal-title":"J. Control Release"},{"key":"B3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","article-title":"Gene therapy for ALS: a review","volume":"29","author":"Amado","year":"2021","journal-title":"Mol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"eadg6518","DOI":"10.1126\/science.adg6518","article-title":"Base editing rescue of spinal muscular atrophy in cells and in mice","volume":"380","author":"Arbab","year":"2023","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e129719","DOI":"10.1172\/jci.insight.129719","article-title":"Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies","volume":"4","author":"Arotcarena","year":"2019","journal-title":"JCI Insight"},{"key":"B7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0301-0082(98)00028-8","article-title":"Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases","volume":"55","author":"Barkats","year":"1998","journal-title":"Prog. Neurobiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nbd.2011.05.026","article-title":"Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease","volume":"44","author":"Bartus","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1126\/science.abq5622","article-title":"Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies","volume":"379","author":"Baughn","year":"2023","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2018.05.005","article-title":"Epigenetic regulation in neurodegenerative diseases","volume":"41","author":"Berson","year":"2018","journal-title":"Trends Neurosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1126\/science.281.5384.1851","article-title":"Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1","volume":"281","author":"Bruijn","year":"1998","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/82_2017_52","article-title":"ER stress and neurodegenerative disease: a cause or effect relationship?","volume":"414","author":"Cabral-Miranda","year":"2018","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/pharmaceutics15051502","article-title":"Cationic polymers as transfection reagents for nucleic acid delivery","volume":"15","author":"Cai","year":"2023","journal-title":"Pharmaceutics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","article-title":"A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease","volume":"27","author":"Cearley","year":"2007","journal-title":"J. Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ymthe.2018.02.029","article-title":"Targeting amyloid-beta precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-beta production","volume":"26","author":"Chang","year":"2018","journal-title":"Mol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.09.002","article-title":"Neuronal stathmins: a family of phosphoproteins cooperating for neuronal development, plasticity and regeneration","volume":"126","author":"Chauvin","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1016\/j.cell.2023.10.004","article-title":"Circuit-specific gene therapy reverses core symptoms in a primate Parkinson's disease model","volume":"186","author":"Chen","year":"2023","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1021\/acs.jmedchem.8b01291","article-title":"Discovery of small molecule splicing modulators of survival motor neuron-2 (smn2) for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Cheung","year":"2018","journal-title":"J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1474-4422(17)30401-5","article-title":"Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications","volume":"17","author":"Chia","year":"2018","journal-title":"Lancet Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neuint.2017.08.002","article-title":"Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia","volume":"117","author":"Chiang","year":"2018","journal-title":"Neurochem. Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/mds.28258","article-title":"GDNF\/RET signaling pathway activation eliminates lewy body pathology in midbrain dopamine neurons","volume":"35","author":"Chmielarz","year":"2020","journal-title":"Mov. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/mt.2016.84","article-title":"In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy","volume":"24","author":"Choudhury","year":"","journal-title":"Mol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/mt.2015.231","article-title":"Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector","volume":"24","author":"Choudhury","year":"","journal-title":"Mol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000201005","article-title":"Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial","volume":"98","author":"Christine","year":"2022","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/biom11040612","article-title":"Treatment options for motor and non-motor symptoms of Parkinson's disease","volume":"11","author":"Church","year":"2021","journal-title":"Biomolecules"},{"key":"B28","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/mt.2010.248","article-title":"Anterograde axonal transport of AAV2-GDNF in rat basal ganglia","volume":"19","author":"Ciesielska","year":"2011","journal-title":"Mol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00002512-199914040-00003","article-title":"Therapeutic potential of nerve growth factors in Parkinson's disease","volume":"14","author":"Collier","year":"1999","journal-title":"Drugs Aging"},{"key":"B30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/mds.29346","article-title":"A phase 1B trial in GBA1-associated Parkinson's disease of BIA-28-6156, a glucocerebrosidase activator","volume":"38","author":"De Heijer","year":"2023","journal-title":"Mov. Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"key":"B34","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1006846","DOI":"10.1371\/journal.pgen.1006846","article-title":"Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis","volume":"13","author":"Dietrich","year":"2017","journal-title":"PLoS Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","article-title":"Glucocerebrosidase and its relevance to Parkinson disease","volume":"14","author":"Do","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2359","DOI":"10.1038\/cddis.2016.263","article-title":"Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model","volume":"7","author":"Drinkut","year":"2016","journal-title":"Cell Death Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.ymthe.2023.03.028","article-title":"The unfolded protein response transcription factor XBP1s ameliorates Alzheimer's disease by improving synaptic function and proteostasis","volume":"31","author":"Duran-Aniotz","year":"2023","journal-title":"Mol. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington's disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1038\/s41467-023-42876-1","article-title":"Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model","volume":"14","author":"Fang","year":"2023","journal-title":"Nat. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1038\/s41467-023-39552-9","article-title":"Genome-wide screening in pluripotent cells identifies Mtf1 as a suppressor of mutant huntingtin toxicity","volume":"14","author":"Ferlazzo","year":"2023","journal-title":"Nat. Commun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.arr.2021.101385","article-title":"Gene targeting techniques for Huntington's disease","volume":"70","author":"Fields","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"eaar3952","DOI":"10.1126\/sciadv.aar3952","article-title":"In vivo genome editing improves motor function and extends survival in a mouse model of ALS","volume":"3","author":"Gaj","year":"2017","journal-title":"Sci. Adv."},{"key":"B48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41583-024-00829-7","article-title":"Gene therapy for CNS disorders: modalities, delivery and translational challenges","volume":"25","author":"Gao","year":"2024","journal-title":"Nat. Rev. Neurosci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"580874","DOI":"10.3389\/fonc.2020.580874","article-title":"Diagnostic and therapeutic potential of extracellular vesicles in B-cell malignancies","volume":"10","author":"Gargiulo","year":"2020","journal-title":"Front. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nbd.2007.04.003","article-title":"AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease","volume":"27","author":"Gasmi","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1750-3639.2009.00284.x","article-title":"TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis","volume":"20","author":"Giordana","year":"2010","journal-title":"Brain Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4172\/2157-7412.1000128","article-title":"The molecular chaperone GRP78\/BiP as a therapeutic target for neurodegenerative disorders: a mini review","volume":"4","author":"Gorbatyuk","year":"2013","journal-title":"J. Genet. Syndr. Gene Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/538S1a","article-title":"Parkinson's disease","volume":"538","author":"Grayson","year":"2016","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1093\/hmg\/ddaa179","article-title":"Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation","volume":"29","author":"Griciuc","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"key":"B57","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.omtn.2018.03.007","article-title":"CRISPR\/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer's disease","volume":"11","author":"Gy\u00f6rgy","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/mt.2010.106","article-title":"Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC","volume":"18","author":"Hadaczek","year":"2010","journal-title":"Mol. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn.2016.38","article-title":"The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease","volume":"17","author":"Haeusler","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"43741","DOI":"10.1074\/jbc.M112.372318","article-title":"Ubiquitin-specific protease 9x deubiquitinates and stabilizes the spinal muscular atrophy protein-survival motor neuron","volume":"287","author":"Han","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1038\/s41467-023-39554-7","article-title":"AAV11 enables efficient retrograde targeting of projection neurons and enhances astrocyte-directed transduction","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1002\/j.1460-2075.1988.tb03306.x","article-title":"Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor","volume":"7","author":"Herz","year":"1988","journal-title":"Embo J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"115475","DOI":"10.1016\/j.ejmech.2023.115475","article-title":"Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives","volume":"256","author":"Hu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"B65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4103\/NRR.NRR-D-23-01277","article-title":"AAV mediated carboxyl terminus of Hsp70 interacting protein overexpression mitigates the cognitive and pathological phenotypes of APP\/PS1 mice","volume":"20","author":"Hu","year":"2025","journal-title":"Neural Regen Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases","volume":"72","author":"Huang","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"212r","DOI":"10.1126\/scitranslmed.3007000","article-title":"Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain","volume":"5","author":"Hudry","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1080\/15548627.2018.1491489","article-title":"The lysosomal membrane protein LAMP2A promotes autophagic flux and prevents SNCA-induced Parkinson disease-like symptoms in the Drosophila brain","volume":"14","author":"Issa","year":"2018","journal-title":"Autophagy"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ymthe.2024.03.024","article-title":"APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease","volume":"32","author":"Jackson","year":"2024","journal-title":"Mol. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jalz.2017.12.006","article-title":"The cost of Alzheimer's disease in China and re-estimation of costs worldwide","volume":"14","author":"Jia","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","article-title":"Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study","volume":"5","author":"Jia","year":"2020","journal-title":"Lancet Public Health"},{"key":"B74","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"key":"B75","doi-asserted-by":"publisher","first-page":"11753","DOI":"10.1021\/acsnano.3c13150","article-title":"Biomimetic nanovesicles as a dual gene delivery system for the synergistic gene therapy of Alzheimer's disease","volume":"18","author":"Jiang","year":"2024","journal-title":"ACS Nano."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41591-021-01522-3","article-title":"Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain","volume":"27","author":"Keiser","year":"2021","journal-title":"Nat. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s41467-022-28653-6","article-title":"An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion","volume":"13","author":"Keller","year":"2022","journal-title":"Nat. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ymthe.2004.02.016","article-title":"AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease","volume":"9","author":"Kells","year":"2004","journal-title":"Mol. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neuron.2020.08.022","article-title":"ALS genetics: gains, losses, and implications for future therapies","volume":"108","author":"Kim","year":"2020","journal-title":"Neuron"},{"key":"B82","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/d41573-022-00121-2","article-title":"LRRK2 inhibitor progresses for Parkinson disease","volume":"21","author":"Kingwell","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B83","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1006\/mcne.2000.0929","article-title":"Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors","volume":"17","author":"K\u00fcgler","year":"2001","journal-title":"Mol. Cell Neurosci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1038\/s41467-023-44319-3","article-title":"ANKS1A regulates LDL receptor-related protein 1 (LRP1)-mediated cerebrovascular clearance in brain endothelial cells","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"B86","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"B87","doi-asserted-by":"publisher","first-page":"11923","DOI":"10.1523\/JNEUROSCI.2795-06.2006","article-title":"Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice","volume":"26","author":"Levites","year":"2006","journal-title":"J. Neurosci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"7736","DOI":"10.3390\/ijms24097736","article-title":"Viral vector-based gene therapy","volume":"24","author":"Li","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1093\/nar\/gku402","article-title":"CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences","volume":"42","author":"Lin","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","article-title":"APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types","volume":"98","author":"Lin","year":"2018","journal-title":"Neuron"},{"key":"B92","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B93","doi-asserted-by":"publisher","first-page":"111028","DOI":"10.1016\/j.msec.2020.111028","article-title":"Actively targeted gold nanoparticle composites improve behavior and cognitive impairment in Parkinson's disease mice","volume":"114","author":"Liu","year":"","journal-title":"Mater Sci. Eng. C Mater Biol. Appl."},{"key":"B94","doi-asserted-by":"publisher","first-page":"eaba3967","DOI":"10.1126\/sciadv.aba3967","article-title":"Targeted exosome coating gene-chem nanocomplex as \u201cnanoscavenger\u201d for clearing \u03b1-synuclein and immune activation of Parkinson's disease","volume":"6","author":"Liu","year":"","journal-title":"Sci. Adv."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e20220007","DOI":"10.1002\/INMD.20220007","article-title":"Extracellular vesicle-based nucleic acid delivery","volume":"1","author":"Lu","year":"2023","journal-title":"Interdiscip. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"21702","DOI":"10.1021\/jacs.0c08395","article-title":"Self-protecting biomimetic nanozyme for selective and synergistic clearance of peripheral amyloid-\u03b2 in an Alzheimer's disease model","volume":"142","author":"Ma","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"B97","doi-asserted-by":"publisher","first-page":"20230147","DOI":"10.1002\/EXP.20230147","article-title":"A perspective of lipid nanoparticles for RNA delivery","volume":"4","author":"Ma","year":"2024","journal-title":"Exploration"},{"key":"B98","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"B99","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00441-020-03227-4","article-title":"Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease","volume":"382","author":"Mahato","year":"2020","journal-title":"Cell Tissue Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1874357901004010123","article-title":"HSV recombinant vectors for gene therapy","volume":"4","author":"Manservigi","year":"2010","journal-title":"Open Virol. J."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gt.2011.216","article-title":"Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems","volume":"20","author":"Mattar","year":"2013","journal-title":"Gene Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol. Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B107","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.devcel.2021.02.010","article-title":"Autophagy and organelle homeostasis in cancer","volume":"56","author":"Miller","year":"2021","journal-title":"Dev. Cell"},{"key":"B108","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"16046","DOI":"10.1038\/mtm.2016.46","article-title":"Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs","volume":"3","author":"Miyanohara","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B111","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0169-328X(86)90020-3","article-title":"Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons","volume":"387","author":"Mobley","year":"1986","journal-title":"Brain Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-021-03770-2","article-title":"Regulated control of gene therapies by drug-induced splicing","volume":"596","author":"Monteys","year":"2021","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat. Neurosci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and microrna in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e051871","DOI":"10.1002\/alz.051871","article-title":"Results of the first-in-human, randomized, double-blind, placebo-controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with mild Alzheimer's disease","volume":"17","author":"Mummery","year":"2021","journal-title":"Alzheimer's Dementia"},{"key":"B116","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/10430340252792486","article-title":"Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes","volume":"13","author":"Muramatsu","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"B117","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.expneurol.2008.10.004","article-title":"Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery","volume":"215","author":"Nagahara","year":"2009","journal-title":"Exp. Neurol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"B120","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.addr.2021.03.002","article-title":"Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues","volume":"173","author":"Naseri Kouzehgarani","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B121","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.chest.2018.06.035","article-title":"Respiratory failure in amyotrophic lateral sclerosis","volume":"155","author":"Niedermeyer","year":"2019","journal-title":"Chest"},{"key":"B122","doi-asserted-by":"publisher","first-page":"11939","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1002\/mds.22062","article-title":"Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease","volume":"23","author":"Obeso","year":"2008","journal-title":"Mov. Disord."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e36197","DOI":"10.7759\/cureus.36197","article-title":"Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (Zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"key":"B125","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1093\/nar\/gkad259","article-title":"Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy","volume":"51","author":"Ottesen","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"key":"B127","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd1775","article-title":"Design and development of polymers for gene delivery","volume":"4","author":"Pack","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B128","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","article-title":"In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease","volume":"22","author":"Park","year":"2019","journal-title":"Nat. Neurosci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"72r","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.nurt.2008.02.003","article-title":"Treatment of Parkinson's disease with trophic factors","volume":"5","author":"Peterson","year":"2008","journal-title":"Neurotherapeutics"},{"key":"B132","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: the Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/mds.28762","article-title":"Prevalence of Parkinson's disease: a community-based study in China","volume":"36","author":"Qi","year":"2021","journal-title":"Mov. Disord."},{"key":"B134","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41586-020-2388-4","article-title":"Reversing a model of Parkinson's disease with in situ converted nigral neurons","volume":"582","author":"Qian","year":"2020","journal-title":"Nature"},{"key":"B135","doi-asserted-by":"publisher","first-page":"111438","DOI":"10.1016\/j.mad.2021.111438","article-title":"TREM2, microglia, and Alzheimer's disease","volume":"195","author":"Qin","year":"2021","journal-title":"Mech. Ageing Dev."},{"key":"B136","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease","volume":"10","author":"Rafii","year":"2014","journal-title":"Alzheimers Dement"},{"key":"B137","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of huntington's disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3233\/JPD-202400","article-title":"Neuroprotective potential of a small molecule RET agonist in cultured dopamine neurons and hemiparkinsonian rats","volume":"11","author":"Renko","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"B140","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.nbd.2014.09.013","article-title":"AAV shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo","volume":"73","author":"Saal","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"B142","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.3390\/ijms22147545","article-title":"How far are non-viral vectors to come of age and reach clinical translation in gene therapy?","volume":"22","author":"Sainz-Ramos","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B143","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12017-013-8261-y","article-title":"Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease","volume":"16","author":"Sandhir","year":"2014","journal-title":"Neuromolecular Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"B147","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/15476286.2018.1454812","article-title":"Oligonucleotide therapeutics in neurodegenerative diseases","volume":"15","author":"Scoles","year":"2018","journal-title":"RNA Biol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ymthe.2022.11.002","article-title":"AAV-mediated neuronal expression of an scFv antibody selective for Abeta oligomers protects synapses and rescues memory in Alzheimer models","volume":"31","author":"Selles","year":"2023","journal-title":"Mol. Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1089\/10430340050083243","article-title":"Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease","volume":"11","author":"Shen","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"B150","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1093\/hmg\/ddw286","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B151","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","article-title":"Progress in gene therapy for neurological disorders","volume":"9","author":"Simonato","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2174\/1570159X18666200128121920","article-title":"Recent trends in the management of Alzheimer's disease: current therapeutic options and drug repurposing approaches","volume":"18","author":"Singh","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/biomedicines12071523","article-title":"Recombinant adeno-associated virus vectors for gene therapy of the central nervous system: delivery routes and clinical aspects","volume":"12","author":"S\u0142yk","year":"2024","journal-title":"Biomedicines"},{"key":"B154","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/17425240903540205","article-title":"Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics","volume":"7","author":"Soderquist","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"B155","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature17939","article-title":"Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression","volume":"533","author":"Soldner","year":"2016","journal-title":"Nature"},{"key":"B156","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1073\/pnas.1014715108","article-title":"Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage","volume":"108","author":"Stoica","year":"2011","journal-title":"Proc. Natl. Acad Sci. USA"},{"key":"B158","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","article-title":"MAPT mutations, tauopathy, and mechanisms of neurodegeneration","volume":"99","author":"Strang","year":"2019","journal-title":"Lab. Invest."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1089\/hum.2009.103","article-title":"Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys","volume":"20","author":"Su","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"B160","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1038\/mtna.2014.30","article-title":"Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies","volume":"3","author":"Sud","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B161","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","article-title":"Gene therapy for neurodegenerative diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurotherapeutics"},{"key":"B162","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41467-018-07971-8","article-title":"CRISPR\/Cas9 editing of APP C-terminus attenuates \u03b2-cleavage and promotes \u03b1-cleavage","volume":"10","author":"Sun","year":"2019","journal-title":"Nat. Commun."},{"key":"B163","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41593-020-00778-1","article-title":"Gene-based therapies for neurodegenerative diseases","volume":"24","author":"Sun","year":"2021","journal-title":"Nat. Neurosci."},{"key":"B164","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.28251","article-title":"Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells","volume":"63","author":"Sun","year":"2016","journal-title":"Hepatology"},{"key":"B165","doi-asserted-by":"publisher","first-page":"102084","DOI":"10.1016\/j.omtn.2023.102084","article-title":"Neuronal-type-specific epigenome editing to decrease SNCA expression: implications for precision medicine in synucleinopathies","volume":"35","author":"Sun","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B166","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B168","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11010-020-03834-3","article-title":"Gene therapy: a double-edged sword with great powers","volume":"474","author":"Tang","year":"2020","journal-title":"Mol. Cell Biochem."},{"key":"B169","doi-asserted-by":"publisher","first-page":"e138207","DOI":"10.1172\/JCI138207","article-title":"Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43-related neurodegeneration","volume":"133","author":"Tejwani","year":"2023","journal-title":"J. Clin. Invest."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e2106685118","DOI":"10.1073\/pnas.2106685118","article-title":"LRRK2 plays essential roles in maintaining lung homeostasis and preventing the development of pulmonary fibrosis","volume":"118","author":"Tian","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B171","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/373335a0","article-title":"Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo","volume":"373","author":"Tomac","year":"1995","journal-title":"Nature"},{"key":"B173","doi-asserted-by":"publisher","first-page":"7567","DOI":"10.1038\/s41598-019-43772-9","article-title":"Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting alpha-synuclein as a novel therapy for Parkinson's disease","volume":"9","author":"Uehara","year":"2019","journal-title":"Sci. Rep."},{"key":"B174","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1146\/annurev-biochem-061516-045049","article-title":"Propagation of protein aggregation in neurodegenerative diseases","volume":"88","author":"Vaquer-Alicea","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"B175","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12951-023-02044-5","article-title":"Emerging non-viral vectors for gene delivery","volume":"21","author":"Wang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1073\/pnas.1524575113","article-title":"Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B177","doi-asserted-by":"publisher","first-page":"e20240031","DOI":"10.1002\/INMD.20240031","article-title":"Adeno-associated virus vectors for gene therapy\u2014focusing on melanoma","volume":"2","author":"Wang","year":"2024","journal-title":"Interdiscip. Med."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41401-021-00810-5","article-title":"PINK1 overexpression prevents forskolin-induced tau hyperphosphorylation and oxidative stress in a rat model of Alzheimer's disease","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/0896-6273(95)90259-7","article-title":"An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria","volume":"14","author":"Wong","year":"1995","journal-title":"Neuron"},{"key":"B180","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.ymthe.2017.08.011","article-title":"Combining constitutively active rheb expression and chondroitinase promotes functional axonal regeneration after cervical spinal cord injury","volume":"25","author":"Wu","year":"2017","journal-title":"Mol. Ther."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00109-023-02382-9","article-title":"Dual roles of UPR(er) and UPR(mt) in neurodegenerative diseases","volume":"101","author":"Xu","year":"2023","journal-title":"J. Mol. Med."},{"key":"B182","doi-asserted-by":"publisher","first-page":"20210081","DOI":"10.1002\/EXP.20210081","article-title":"Carrier strategies boost the application of CRISPR\/Cas system in gene therapy","volume":"2","author":"Xu","year":"2022","journal-title":"Exploration"},{"key":"B183","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"B184","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41551-023-01007-3","article-title":"Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease","volume":"7","author":"Yan","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"B185","doi-asserted-by":"publisher","first-page":"100581","DOI":"10.1016\/j.xinn.2024.100581","article-title":"Shedding light on gene therapy of Parkinson's disease in non-human primates","volume":"5","author":"Yan","year":"2024","journal-title":"Innovation"},{"key":"B186","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4103\/1673-5374.346463","article-title":"Knockdown of polypyrimidine tract binding protein facilitates motor function recovery after spinal cord injury","volume":"18","author":"Yang","year":"2023","journal-title":"Neural. Regen. Res."},{"key":"B187","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1566523052997514","article-title":"Retroviral gene therapy: safety issues and possible solutions","volume":"5","author":"Yi","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"B188","doi-asserted-by":"publisher","first-page":"e2306583","DOI":"10.1002\/adma.202306583","article-title":"The landscape of biomimetic nanovesicles in brain diseases","volume":"36","author":"You","year":"2024","journal-title":"Adv. Mater."},{"key":"B189","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA drugs and RNA targets for small molecules: principles, progress, and challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"B190","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-neuro-071013-014300","article-title":"Apolipoprotein E in Alzheimer's disease: an update","volume":"37","author":"Yu","year":"2014","journal-title":"Annu. Rev. Neurosci."},{"key":"B191","doi-asserted-by":"publisher","first-page":"eadd6696","DOI":"10.1126\/science.add6696","article-title":"TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease","volume":"381","author":"Zhang","year":"2023","journal-title":"Science"},{"key":"B192","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate alpha-synuclein inclusion formation in a Parkinson's disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B193","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","article-title":"Apolipoprotein E, receptors, and modulation of Alzheimer's disease","volume":"83","author":"Zhao","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"B194","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J. Clin. Invest."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1089\/hum.2017.255","article-title":"Seamless genetic conversion of SMN2 to SMN1 via CRISPR\/Cpf1 and single-stranded oligodeoxynucleotides in spinal muscular atrophy patient-specific induced pluripotent stem cells","volume":"29","author":"Zhou","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B196","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/jnnp-2016-315018","article-title":"Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"88","author":"Zou","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B197","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.bbrc.2012.03.033","article-title":"AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease","volume":"420","author":"Zuleta","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1515255\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:25:55Z","timestamp":1746681955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1515255\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":197,"alternative-id":["10.3389\/fnins.2025.1515255"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2025.1515255","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"1515255"}}